Zodia Custody Partners With Solidus Labs to Bolster Financial Crime Transaction Monitoring Capabilities
19.9.2024 13:00:00 CEST | Business Wire | Press release
Zodia Custody, a leading institution-first digital asset custodian backed by Standard Chartered, SBI Holdings, Northern Trust, and National Australia Bank, today announced a partnership with Solidus Labs, a category-definer in crypto-native compliance and security solutions. This collaboration will bolster Zodia Custody's transaction monitoring capabilities, ensuring comprehensive coverage of both onchain and offchain transactions—further optimizing Zodia’s approach to financial crime risk identification and mitigation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240919602019/en/
Zodia Custody selects Solidus Labs to enhance crypto transaction monitoring capabilities (Photo: Business Wire)
Solidus Labs' transaction monitoring solution features an asset-agnostic architecture that integrates advanced machine learning and behavioral analytics to provide comprehensive coverage of both fiat and digital asset transactions across any blockchain. This offers Zodia Custody unparalleled flexibility in its monitoring efforts, synthesizing onchain and offchain risk signals to enable early detection of suspicious activities, including fraud, market manipulation, and money laundering, while minimizing false positives.
In the Digital Asset ecosystem which is constantly innovating, robust financial crime controls are of paramount importance, and it is essential that firms continuously seek opportunities for enhancement despite operating in jurisdictions with well-established Anti-Money Laundering regulation, and more recent frameworks like the European Union’s Markets in Crypto-Assets Regulation (MiCA) providing clarity for the industry. Zodia Custody’s use of Solidus Labs’ cutting-edge solutions, and the associated partnership between firms is a welcome addition to the digital assets space, for enhancing financial crime risk identification, ensuring ongoing compliance and enabling growth for institutional investors.
Mike Sadarangani, Group Head of Financial Crime Compliance at Zodia Custody, said: “Financial Crime detection and prevention is the cornerstone of enabling innovation and ensuring that businesses in the digital asset space can thrive by preventing the misuse by illicit actors. It brings clarity and certainty to a constantly evolving environment. Our partnership with Solidus Labs further enhances our risk-based approach to on-chain and off-chain transaction monitoring, keeping us at the forefront of regulatory compliance, and in-line with the standards that institutional investors recognize and trust.”
“Zodia Custody’s forward-thinking approach to compliance aligns perfectly with Solidus Labs’ mission to enable safe and secure digital asset trading,” said Asaf Meir, CEO and Founder of Solidus Labs. “Our transaction monitoring modules will empower Zodia to detect anomalies in real-time, ensuring a proactive defense against financial crime across both centralized and decentralized ecosystems. This collaboration solidifies Zodia Custody’s position as a compliance leader in the digital asset space, while further strengthening their institutional offerings.”
Solidus Labs’ HALO Transaction Monitoring (TM) module ensures that compliance teams can get holistic views on customer activity by combining onchain activity with your more traditional offchain TM typologies. This real-time risk management capability provides Zodia Custody with a powerful layer of additional protection, helping the firm maintain its reputation as a trusted, secure custodian for institutional investors.
About Zodia Custody
Zodia Custody is the leading institution-first digital asset custodian by Standard Chartered, in association with Northern Trust, SBI Holdings and National Australia Bank. It enables institutional investors around the globe to realize the full potential of the digital asset future – simply, safely, and without compromise. Through the combination of leading technology, custody, governance and compliance, Zodia Custody satisfies the complex needs of institutional investors.
Zodia Custody implements the requirements of the 5AMLD and applies the same standards as Standard Chartered relating to AML, FCC, and KYC. It implements the requirements of the FATF Travel Rule. Zodia Custody Limited is registered in the UK with the FCA as a crypto asset business under the Money Laundering, Terrorist Financing and Transfer of Funds Regulations 2017. Zodia Custody (Ireland) Limited is registered with the Central Bank of Ireland as a VASP under Criminal Justice (Money Laundering and Terrorist Financing) Act 2010 (as amended). Zodia Custody (Ireland) Limited was established in Ireland in August 2021. Zodia Custody Limited is registered with the CSSF in Luxembourg as a Virtual Asset Service Provider in accordance with article 7-1 (2) of the law dated 12 November 2004 on the fight against money laundering and terrorist financing, as amended. Zodia Custody (Hong Kong) Limited is registered with the Registry for Trust and Company Service Provider with License Number TC009245 under the Anti-Money Laundering and Counter-Terrorist Financing Ordinance (AMLO), Cap. 615 in respect of its custodial activities in digital assets.
High-resolution images and logos can be found here.
For more information about Zodia Custody: LinkedIn, Twitter.
About Solidus Labs
Solidus Labs is the category-definer for crypto-native security and compliance solutions—specializing in trade surveillance, transaction monitoring, and staking guard. Our mission is to enable safe crypto trading throughout the investment journey across all centralized and DeFi markets. As the founder of industry-leading initiatives like the Crypto Market Integrity Coalition and DACOM Summit, Solidus is deeply committed to ushering in the financial markets of tomorrow.
To learn more, please visit: https://soliduslabs.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240919602019/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom